Age equivalents (months)
 
Group A (PlaceboMinocycline) (N = 11)

Group B1 (MinocyclinePlacebo) (N = 11)

Group B2 (MinocyclineMinocycline) (N = 10)

p value

Development index

Baseline

12·55 (6·53)

13·09 (6·31)

10·80 (6·33)

0·699

Week 16

15·55 (5·93)

13·90 (6·65)

12·00 (7·64)

0·495

Absolute mean change

3·00 (3·63)

0·72 (2·56)

1·20 (5·53)

0·401

Secondary analysis: Development index change after 8 week or 16 week total treatment duration with minocycline

Age equivalents(months)
 
Minocycline 8 weeks^{a} (N = 22)

Minocycline16 weeks^{b} (N = 10)
 
Absolute mean differences, 95% CI

Development index

Absolute mean change

1·86 (3·35)

1·20 (5·53)
 
0·663, 95% CI (−2·55–3·88)

Secondary analysis: Period effect analysis in the crossover substudy

 
PERIOD 1 (N = 22)

PERIOD 2 (N = 22)
 
Absolute mean differences, 95% CI, p value

Development index

Absolute mean change

2·21 (3·37)

− 0·34 (3·24)
 
2·55, 95% CI (0·80–5·05)
